StreetInsider.com News Articles

This biotech stock still Wolfe's top pick as multiple catalysts loomh

Mon, 31 Aug 2026 08:00:00 -0400

Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.

The brokerage reiterated an Outperform rating on Dianthus Therapeutics (NASDAQ: DNTH) and raised its price target to $141, up from $109, implying more than 33% upside from the last closing price. Analyst Andy Chen said he expects the stock to unlock value through its myasthenia gravis (MG) program, which he views as "a low-risk shot & potentially bigger upside on a readthrough from Biogen's litifilimab & Vor's MG

This biotech stock still Wolfe's top pick as multiple catalysts loomh

Mon, 31 Aug 2026 08:00:00 -0400

Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.

This biotech stock still Wolfe's top pick as multiple catalysts loomh

Mon, 31 Aug 2026 08:00:00 -0400

Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.

This biotech stock still Wolfe's top pick as multiple catalysts loomh

Mon, 31 Aug 2026 08:00:00 -0400

Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.

This biotech stock still Wolfe's top pick as multiple catalysts loomh

Mon, 31 Aug 2026 08:00:00 -0400

Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.

This biotech stock still Wolfe's top pick as multiple catalysts loomh

Mon, 31 Aug 2026 08:00:00 -0400

Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.

Form 4 Vor Biopharma Inc. For: Aug 24 Filed by: RA Capital Healthcare Fund LP

Wed, 26 Aug 2026 18:29:00 -0400

si-local-file:///var/storage/secattach/20260826/26983122.html

Form 4 Vor Biopharma Inc. For: Aug 24 Filed by: RA Capital Healthcare Fund LP

Wed, 26 Aug 2026 18:29:00 -0400

si-local-file:///var/storage/secattach/20260826/26983122.html

Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26932341.html

Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26932341.html

Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: Frazier Life Sciences Public Fund, L.P.

Fri, 14 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26931424.html

Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: Frazier Life Sciences Public Fund, L.P.

Fri, 14 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26931424.html

Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: Verve Capital Ltd

Thu, 13 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26921825.html

Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: Verve Capital Ltd

Thu, 13 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26921825.html

Form 10-Q Vor Biopharma Inc. For: Jun 30

Tue, 11 Aug 2026 09:31:00 -0400

si-local-file:///var/storage/secattach/20260811/26902930.html

Form 10-Q Vor Biopharma Inc. For: Jun 30

Tue, 11 Aug 2026 09:31:00 -0400

si-local-file:///var/storage/secattach/20260811/26902930.html

Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update